INNATE PHARMA : Le pipe IPH s'étoffe = intérêt WS et Euronext malgré spéculation secteur Bios

EL_CAMINO

16 sept. 2021 •18:34

Le pipe s'étoffe donc WS et Euronext comme AZN et SANOFI sont dans l'intérêt même si titre travaillé et spéculatif (secteur bios) - Voice le pipeactkuel et statut:
LACUTAMAB (KIR3DL2) - Proprietary
Advanced T Cell Lymphoma: Serazy Syndrom & Mycosis Fungoid - TELLOMAK Study with FDA Fast Track and EMA Prime (Phase 2) - Data expected 2022
New - PTCL (combo with GemOx): Phase 2 start H2 2021 and PTCL (mono): Phase 1B start H2 2021

MONALIZUMAB (NKG2A)- Co-development AZN
1) Cancer + COVID-19 (NCT04333914) - IMMUNONCOVID Study (phase 2) - Stoppage?
2) HER-2 Positive breast cancer (NCT04307329): MIMOSA Study - MONALIZUMAB + TRASTUZUMAB (Phase 2) - Estimated May 2023
3) NSCLC (NCT03822351): COAST Study - DURVALUMAB + MONALIZUMAB (Phase 2) - Estimated July 2023
4) Head & Neck Cancer (NCT04590963): INTERLINK-1 Study - CETUXIMAB + MONALIZUMAB (Phase 3) - Post anti-PD-1/L1 Phase 3 data expected 2022 and Phase 2 data expected H2 2021
New: 5) Non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC): Phase 2 data at ESMO 2021

AVDORALIMAB (C5AR) - Proprietary
1) COVID-19 severe Pneumonia (NCT04371367): FORCE Study (Phase 2) - Failure
2) Bullous Pemphigoid (NCT04563923) - (Phase 2) - Data postponed 2022

IPH5201 (Co-development AZN)
Cancer solid tumors (CD39) - Phase 1: Data expected 2022

IPH5301 (Proprietary)
Cancer solid tumors (CD73) - Phase 1 start H2 2021 -

ANKET Platform (jamais vu en préclinique selon VIVIER):
IPH6101 (tri-specific) - Co-development SANOFI - IPH6101 in IND-enabling studies
IPH62 (tri-specific) - Co-development SANOFI - Pre-clinical
IPH64 (tri-specific) - Co-development AZN - Pre-clinical
IPH65 (tetra-specific) - Proprietary - Pre-clinical

Others:
IPH62 - Co-development AZN - Pre-clinical
IPH25 and IPH26 (Siglec-9) - Co-development AZN - Pre-clinical
IPH43 (MICA/B ADC) - Co-development AZN - Pre-clinical